Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RX-10045 in Allergic Conjunctivitis
NCT01639846Phase 2Completed
- Sponsor
- C.T. Development America
- Start
- Jul 2012
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic conjunctivitis (AC) comparing RX-10045 active arm with Vehicle for RX-10045 arm (2 arms). Primary endpoints: Ocular itching at 14 days and Conjunctival redness at 14 days. Started Jul 2012; status: completed.
02
Drugs
navamepent
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT01639846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01639846.